Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessUnitedHealth Group Updates Guidance

UnitedHealth Group Updates Guidance

Add to Favorite
Added to Favorite


UnitedHealth Group Incorporated (NYSE:UNH) issued its fiscal 2023 EPS guidance of $24.40—24.90 (vs. Street’s $24.92). Revenues are projected to be robust at $357—360 billion (vs. Street’s $352 billion), while cash flows are expected to be strong at $27—28 billion.
The mid-point of the new EPS outlook equates to 12% growth over the mid-point of 2022 guidance of $21.85—22.05.
Analysts at Oppenheimer estimate that the company has beaten its initial mid-point by an average of 4.5% over the last five and ten years. At first glance, the outlook appears solid, especially considering the company’s conservatism and consistency are likely to drive an upside to this outlook.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Advance Auto Parts Downgraded to Sell Amid Earnings Miss and Weak Outlook

CFRA analysts downgraded Advance Auto Parts (NYSE:AAP) from Hold...

Guggenheim Reiterates Buy Rating on Cabaletta Bio Amid Promising Data

Guggenheim analysts reaffirmed a Buy rating and a $23...

Goldman Sachs Initiates Neutral Coverage on Doximity, Highlights Balanced Growth Potential

Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with...

JPMorgan Downgrades bluebird bio to Underweight Following Q3 Results

JPMorgan analysts downgraded bluebird bio (NASDAQ:BLUE) from Neutral to...